Page 22 - ARNM-3-2

Advances in Radiotherapy
& Nuclear Medicine Role of PET/CT in exploring tumor heterogeneity

doi: 10.2967/jnumed.117.197988 neuroendocrine: Differentiation in patients with castrate-
resistant prostate cancer. Clin Nucl Med. 2017;42:1-6.
26. Binderup T, Knigge U, Loft A, et al. 18F-fluorodeoxyglucose
positron emission tomography predicts survival of patients doi: 10.1097/rlu.0000000000001424
with neuroendocrine tumors. Clin Cancer Res. 2010; 36. Pabst KM, Mei R, Lückerath K, et al. Detection of tumour
16:978-985.
heterogeneity in patients with advanced, metastatic
doi: 10.1158/1078-0432.CCR-09-1759 castration-resistant prostate cancer on [ Ga]Ga-/[ F]
68
18
F-PSMA-11/-1007, [ Ga]Ga-FAPI-46 and 2-[ F]FDG PET/
68
18
27. Sanli Y, Garg I, Kandathil A, et al. Neuroendocrine tumor
68
diagnosis and management: Ga-DOTATATE PET/CT. AJR CT: A pilot study. Eur J Nucl Med Mol Imaging. 2024;52:342-353.
Am J Roentgenol. 2018;211:267-277. doi: 10.1007/s00259-024-06891-8
doi: 10.2214/AJR.18.19881 37. Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL,
Haberkorn U. FAPI PET: Fibroblast activation protein
28. Kaewput C, Vinjamuri S. Role of combined Ga DOTA- inhibitor use in oncologic and nononcologic disease.
68
peptides and 18F FDG PET/CT in the evaluation of
gastroenteropancreatic neuroendocrine neoplasms. Radiology. 2023;306:e220749.
Diagnostics. 2022;12:280. doi: 10.1148/radiol.220749
doi: 10.3390/diagnostics12020280 38. Liu X, Liu H, Gao C, Zeng W. Comparison of Ga-FAPI and
68
18 F-FDG PET/CT for the diagnosis of primary and metastatic
29. Zhou Y, Li L, Wang H, et al. Heterogeneous uptake of lesions in abdominal and pelvic malignancies: A systematic
68 Ga-DOTATATE and 18 F-FDG in initial diagnosed
neuroendocrine tumors patients: Which patients are suitable review and meta-analysis. Front Oncol. 2023;13:1093861.
for dual-tracer PET Imaging? Clin Nucl Med. 2024;49:516-520. doi: 10.3389/fonc.2023.1093861
doi: 10.1097/RLU.0000000000005231 39. Xi Y, Sun Y, Gu B, Bian L, Song S. Evaluation of 68Ga-FAPI
PET/CT and 18F-FDG PET/CT for the diagnosis of
30. Nogareda Seoane Z, Mallón Araújo MC, Calatayud Cubes A, recurrent colorectal cancers. Clin Transl Radiat Oncol.
et al. Functional imaging in neuroendocrine tumors:
Assessment of molecular heterogeneity using [ Ga] 2024;49:100848.
68
Ga-DOTA-TOC and [ F]FDG PET/CT. Rev Esp Med Nucl doi: 10.1016/j.ctro.2024.100848
18
Imagen Mol (Engl Ed). 2024;43:500011. 40. Matushita CS, Coelho FARFB, Stasiak CES, et al.
doi: 10.1016/j.remnie.2024.500011 18F-fluoroestradiol positron emission tomography in
patients with breast cancer: A systematic review and meta-
31. Zhang H, Huang R, Cheung NK, et al. Imaging
the norepinephrine transporter in neuroblastoma: analysis. Rev Assoc Med Bras (1992). 2023;69:e2023S116.
A comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer doi: 10.1590/1806-9282.2023S116
Res. 2014;20:2182-2191. 41. Liu C, Gong C, Liu S, et al. 18F-FES PET/CT influences the
doi: 10.1158/1078-0432.CCR-13-1153 staging and management of patients with newly diagnosed
estrogen receptor-positive breast cancer: A retrospective
32. Bian L, Xu J, Li P, Bai L, Song S. Comparison of
18
68 Ga-DOTANOC and F-FDOPA PET/CT for detection comparative study with 18F-FDG PET/CT. Oncologist.
of recurrent or metastatic paragangliomas. Radiol Imaging 2019;24:e1277-e12785.
Cancer. 2024;7(1):e240059. doi: 10.1634/theoncologist.2019-0096
doi: 10.1148/rycan.240059 42. Kurland BF, Peterson LM, Lee JH, et al. Estrogen receptor
binding (FES PET) and glycolytic activity (FDG PET) predict
33. Chang CA, Pattison DA, Tothill RW, et al. (68) progression-free survival on endocrine therapy in patients
Ga-DOTATATE and (18)F-FDG PET/CT in paraganglioma with ER breast cancer. Clin Cancer Res. 2017;23:407-415.
+
and pheochromocytoma: Utility, patterns and heterogeneity.
Cancer Imaging. 2016;16:22. doi: 10.1158/1078-0432.CCR-16-0362
doi: 10.1186/s40644-016-0084-2 43. Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA,
Fracasso P, Welch MJ. Positron emission tomography with
68
34. Wang B, Liu C, Wei Y, et al. A prospective trial of Ga-PSMA 2-[18F] Fluoro-2-deoxy-D-glucose and 16alpha-[18F]
and F-FDG PET/CT in nonmetastatic prostate cancer fluoro-17 beta-estradiol in breast cancer: Correlation with
18
patients with an early PSA progression during castration. estrogen receptor status and response to systemic therapy.
Clin Cancer Res. 2020;26:4551-4558.
Clin Cancer Res. 1996;2:933-9.
doi: 10.1158/1078-0432.CCR-20-0587
44. Gebhart G, Lamberts LE, Wimana Z, et al. Molecular
35. Gofrit ON, Frank S, Meirovitz A, Nechushtan H, Orevi M. imaging as a tool to investigate heterogeneity of advanced
PET/CT With 68Ga-DOTA-TATE for diagnosis of HER2-positive breast cancer and to predict patient outcome

Volume 3 Issue 2 (2025) 14 doi: 10.36922/ARNM025040005